PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.97%
Negative revenue growth while TSM stands at 1.13%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-5.44%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-40.46%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-40.46%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-47.91%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-47.92%
Negative EPS growth while TSM is at 14.18%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-47.92%
Negative diluted EPS growth while TSM is at 14.18%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.71%
Share count expansion well above TSM's 0.01%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.84%
Slight or no buyback while TSM is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-102.24%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-110.44%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
16.48%
10Y revenue/share CAGR under 50% of TSM's 228.15%. Michael Burry would suspect a lasting competitive disadvantage.
-3.71%
Negative 5Y CAGR while TSM stands at 59.84%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
22.63%
3Y revenue/share CAGR at 50-75% of TSM's 43.89%. Martin Whitman would question if the firm lags behind competitor innovations.
-113.86%
Negative 10Y OCF/share CAGR while TSM stands at 255.53%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-102.64%
Negative 5Y OCF/share CAGR while TSM is at 35.26%. Joel Greenblatt would question the firm’s operational model or cost structure.
-105.71%
Negative 3Y OCF/share CAGR while TSM stands at 59.68%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-46.70%
Negative 10Y net income/share CAGR while TSM is at 785.91%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-59.84%
Negative 5Y net income/share CAGR while TSM is 42.36%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
126.44%
3Y net income/share CAGR above 1.5x TSM's 17.47%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
262.34%
10Y equity/share CAGR above 1.5x TSM's 148.40%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
79.80%
5Y equity/share CAGR above 1.5x TSM's 52.37%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
62.83%
3Y equity/share CAGR 1.25-1.5x TSM's 44.94%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.32%
AR growth well above TSM's 13.32%. Michael Burry fears inflated revenue or higher default risk in the near future.
0.71%
Inventory growth well above TSM's 0.01%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
2.80%
Asset growth well under 50% of TSM's 11.16%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
2.69%
Under 50% of TSM's 5.90%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-2.84%
We’re deleveraging while TSM stands at 39.43%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
6.39%
R&D growth drastically higher vs. TSM's 1.39%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
5.75%
SG&A growth well above TSM's 10.34%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.